Results 31 to 40 of about 103,862 (301)
PARP inhibitors in castration-resistant prostate cancer
Cancer Treatment and Research Communications, 2020 Somatic or germline mutations in genes regulating DNA damage repair have been noted in around 20% of patients with advanced prostate cancer. Poly-ADP-ribose polymerase (PARP) inhibitors have shown encouraging efficacy in prostate cancer patients with DNA
Abhishek Tripathi +2 more
doaj +1 more source
PARP Inhibitors in Ovarian Cancer [PDF]
Recent Patents on Anti-Cancer Drug Discovery, 2018 Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical ...
Mittica, Gloria +6 more
openaire +3 more sources
PARP Inhibitors in Pancreatic Cancer
The Cancer Journal, 2021 Abstract Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second leading cause of cancer-related death within the next 10 years. Progress in the treatment of advanced pancreatic cancer has been slow.
Timothy J. Brown, Kim A. Reiss
openaire +3 more sources
Drug Design, Development and Therapy, 2022 Dehua Zhao, Xiaoqing Long, Jisheng Wang Department of Clinical Pharmacy, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, Sichuan, People’s Republic of ChinaCorrespondence: Dehua Zhao; Jisheng Wang, Email zhaoyaoshi0566@163.com ...
Zhao D, Long X, Wang J
doaj
Defective DNA repair mechanisms in prostate cancer: impact of olaparib [PDF]
, 2017 The field of prostate oncology has continued to change dramatically. It has truly become a field that is intensely linked to molecular genetic alterations, especially DNA-repair defects.
De Felice, Francesca +4 more
core +2 more sources
Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
Frontiers in Oncology, 2020 Purpose: PARP inhibitors are a novel targeted anti-cancer drug and a large number of clinical studies on PARP inhibitors have been accomplished. This updated meta-analysis was conducted to evaluate the efficacy and safety of PARP inhibitors in advanced ...
Yifan Jiang +9 more
doaj +1 more source
TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy [PDF]
, 2013 Base damage and topoisomerase I (Top1)-linked DNA breaks are abundant forms of endogenous DNA breakage, contributing to hereditary ataxia and underlying the cytotoxicity of a wide range of anti-cancer agents.
Alagoz +50 more
core +1 more source
Journal of the Turkish German Gynecological Association, 2015 Polyadenosine diphosphate (ADP) ribose polymerase (PARP) lends a panoramic view to the inner mystery of protection of integrity of deoxyribonucleic acid (DNA) in a cell genome. They are a balancing part of an even more dynamic equilibrium of normalcy against daily assaults.
Chinmoy K, Bose, Nirban, Basu
openaire +2 more sources
Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. [PDF]
, 2017 Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing an urgent need to develop new treatment strategies. The liver is the most common site of metastasis.
Aplin, Andrew E. +8 more
core +2 more sources
Inhibition of oncogenic transcription factor REL by the natural product derivative calafianin monomer 101 induces proliferation arrest and apoptosis in human B-lymphoma cell lines [PDF]
, 2015 Increased activity of transcription factor NF-κB has been implicated in many B-cell lymphomas. We investigated effects of synthetic compound calafianin monomer (CM101) on biochemical and biological properties of NF-κB.
Chennamadhavuni, Spandan +4 more
core +2 more sources